Thoralf Lange, Thomas Ernst, Franz X. Gruber, Jacqueline Maier, Michael Cross, Martin C. Müller, Dietger Niederwieser, Andreas Hochhaus, and Markus Pfirrmann. 2013. “The Quantitative Level of T315I Mutated BCR-ABL Predicts for Major Molecular Response to Second-Line Nilotinib or Dasatinib Treatment in Patients With Chronic Myeloid Leukemia”. Haematologica 98 (5). Pavia, Italy, 714-17.